Russian drugmakers confirm plans for localization of foreign vaccines

6 April 2021

Leading Russian pharmaceutical producers Petrovax and R-Pharm have confirmed their plans to speed up implementation of the projects for the production of foreign vaccines within the country, according to recent statements by representatives of the companies.

As a spokesman of Petrovax said in an interview with the Russian Forbes magazine, currently, the company continues international clinical trials of its Convidetsia vaccine against COVID-19, which are conducted in partnership with the Chinese immunological company CanSino Biologics (HK: 6185).

According to Petrovax’ spokesman, the recruitment of volunteers has already been completed, while analytical work is currently being carried out, and all the documents for registration of the vaccine have already been submitted to the Russian Ministry of Health.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK